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Sixteen alkyl-substituted dispiro-1,2,4,5-tetraoxanes (7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecanes)
were synthesized to explore dispiro-1,2,4,5-tetraoxane SAR and to identify tetraoxanes with
better oral antimalarial activity than prototype tetraoxane 1 (WR 148999). The tetraoxanes
were prepared either by peroxidation of the corresponding cyclohexanone derivatives in H2-
SO4/CH3CN or by ozonolysis of the corresponding cyclohexanone methyl oximes. Those
tetraoxanes with alkyl substituents at the 1 and 10 positions were formed as single
stereoisomers, whereas the five tetraoxanes formed without the stereochemical control provided
by alkyl groups at the 1 and 10 positions were isolated as mixtures of diastereomers. Three of
the sixteen tetraoxanes were inactive (IC50’s > 1000 nM), but five (2, 6, 10, 11, 12) had IC50’s
between 10 and 30 nM against the chloroquine-sensitive D6 and chloroquine-resistant W2 clones
of Plasmodium falciparum compared to corresponding IC50’s of 55 and 32 nM for 1 and 8.4
and 7.3 nM for artemisinin. We suggest that tetraoxanes 13, 16, and 17 were inactive and
tetraoxanes 4 and 7 were weakly active due to steric effects preventing or hindering peroxide
bond access to parasite heme. Tetraoxanes 1, 10, 11, and 14, along with artemisinin and
arteether as controls, were administered po b.i.d. (128 mg/kg/day) to P. berghei-infected mice
on days 3, 4, and 5 post-infection. At this dose, tetraoxanes 10, 11, and 14 cured between 40%
and 60% of the infected animals. In comparison, artemisinin and tetraoxane 1 produced no
cures, whereas arteether cured 100% of the infected animals. There was no apparent
relationship between tetraoxane structure and in vitro neurotoxicity, nor was there any
correlation between antimalarial activity and neurotoxicity for these seventeen tetraoxanes.
Introduction
The discovery of artemisinin (qinghaosu), a naturally
occurring endoperoxide sesquiterpene lactone, and sub-
sequent efforts to elucidate its SAR and mechanism of
action established the peroxide bond as the critical
pharmacophoric functional group.1 This discovery was
the beginning of a significant effort to identify syntheti-
cally accessible antimalarial peroxides.2 Among the
most structurally simple class of peroxides to emerge
from these studies were the dispiro-1,2,4,5-tetraoxanes,
as exemplified by 1 (WR 148999).3 Tetraoxanes such as
1 are notable in that they differ considerably in struc-
ture from artemisinin, are readily prepared in one step
from substituted cyclohexanones, and possess good
antimalarial activity, although they do suffer from low
oral activity,4 a defect shared in part by the semisyn-
thetic artemisinins.5 However, tetraoxanes are probably
better known as precursors to macrocyclic lactones via
thermolysis6 and in ozonolysis as undesired side reac-
tion products resulting from dimerization of carbonyl
oxide intermediates.7
Existing data suggest that the low oral activity of
tetraoxane 1 is very likely a function of first-pass drug
metabolism (possibly by CYP 1A2)4 rather than solubil-
ity-limited dissolution, since various tetraoxane formu-
lation strategies and incorporation of polar functional
groups at the 1 and 10 positions in a series of tetraoxane
analogues of 18 both failed to enhance oral antimalarial
activity. Thus, the overarching objective in this work
was to identify tetraoxanes with better oral antimalarial
activity. A secondary, but important qualifying, aim was
to determine alkyl substitution patterns in the dispiro-
1,2,4,5-tetraoxane (7,8,15,16-tetraoxadispiro[5.2.5.2]-
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hexadecane) skeleton associated with maximal antima-
larial potency against Plasmodium falciparum and
minimal neurotoxicty.
Design
Using tetraoxane 1 as a prototype, we designed
tetraoxanes 2-4 bearing larger alkyl groups at the 1
and 10 positions. Tetraoxanes 5 and 6 are dimethyl-
substituted isomers of 2. Tetraoxane 7 with two tert-
butyl groups at the 3 and 12 positions is a conforma-
tionally rigid analogue, but one without alkyl groups
flanking the central tetraoxane heterocycle. Analogues
8-13 form a group of isomeric tetramethyl-substituted
tetraoxanes. Tetraoxane 14 is derived from (-)-men-
thone and 15 is its transpositional isomer. Tetraoxanes
16 and 17 are hexamethyl- and octamethyl-substituted
tetraoxane analogues, respectively.
With this set of tetraoxane analogues, we hoped to
identify a tetraoxane prototype associated with good oral
activity, which we presumed would necessarily possess
good metabolic stability. We had previously hypoth-
esized9 that analogues of tetraoxane 2 with greater
steric bulk flanking the peroxide oxygen atoms might
increase metabolic stability based on the idea that the
peroxide bonds of tetraoxane 1 were the point of
metabolic attack. However, the 1,1,10,10- and 1,5,10,14-
tetramethyl tetraoxane analogues of 1 were completely
inactive,9 suggesting that the two additional axial
methyl groups in these inactive tetraoxanes prevented
their activation to presumed parasiticidal carbon radi-
cals by inhibiting electron transfer from heme or other
iron(II) species.10 From this outcome we hypothesize
that tetraoxane reductive activation in the parasite and
tetraoxane metabolic inactivation by cyp P450s may
both be a function of peroxide bond accessibility and,
therefore, two sides of the same coin.
Results
Chemistry. As previously reported, three tetraoxanes
(4, 6, 7) were prepared by ozonolysis of their corre-
sponding cyclohexanone methyl oximes11 and two (1, 12)
by acid-catalyzed peroxidation reactions.3 The remain-
ing twelve tetraoxanes (2, 3, 5, 8-11, 13-17) were
prepared according to the peroxidation method devel-
oped by McCullough et al.12 in which cyclohexanones
are treated with hydrogen peroxide in H2SO4/CH3CN.
The unoptimized yields ranged from 4% to 68%. The
efficiency of this peroxidation reaction is in part a
function of the solubility of the tetraoxane reaction
product in the reaction solution; higher yield reactions
are those where insoluble tetraoxane products drive the
reaction forward - the converse is true for less efficient
reactions. In some cases, another confounding factor is
formation of the undesired hexaoxonanes, an unpredict-
able outcome that appears to be a function of the
cyclohexanone starting material structure.11
In 1H NMR spectra of tetraoxanes with alkyl substit-
uents at the 1 and 10 positions (2-4, 8-10, 14-16), as
was also the case for tetraoxane 1, characteristic peaks
for the two methine protons at the 1 and 10 positions
fell between 2.75 and 3.35 ppm. In 13C NMR spectra
for each of the tetraoxanes, diagnostic signals were
present at 108-111 ppm corresponding to the spiro
quarternary carbon atoms.
As for 1, we observed that tetraoxanes 2-4 were
formed as single stereoisomers, which we assume are
the centrosymmetric, or meso-(t-10)-1,10, stereoisomers.9
Similarly, tetraoxanes 8-10, 15, and 16 were formed
as single stereoisomers, presumably the centrosymmet-
ric and most thermodynamically stable stereoisomers,
an outcome which we attribute to stereocontrol by the
1,10-dimethyl groups. Attempts to establish their rela-
tive configuration via J values were complicated by
overlapping corresponding signals. Tetraoxanes 5, 6,11
7,11 11, and 12, formed without the stereochemical
control provided by methyl groups at the 1 and 10
positions, were isolated as mixtures of at least two
diastereomers. No isomers exist for tetraoxanes 13 and
17. Tetraoxane 14, generated from (-)-menthone, was
optically active, and although it was formed as a single
stereoisomer, its optical activity indicated that it was
not the centrosymmetric stereoisomer as we had an-
ticipated. Its absolute configuration has not been es-
tablished at this point. Thus, even though some of the
tetraoxanes described above exist as diastereomeric
mixtures, and for others the stereochemical assignments
are incomplete, we thought it worthwhile to screen these
compounds and then initiate additional structural stud-
ies if their antimalarial activities warranted such an
effort.
Antimalarial Activity. The in vitro antimalarial
data in Table 1 reveals that replacing the two methyl
groups in 1 with ethyl groups (2) increased potency
slightly, but this trend did not continue with further
increases in the size (3, 4) of the alkyl substituent. Our
previous data,8 however, indicates that the size of the
substitutuent at the 1 and 10 positions is less critical
when the substituent contains unsaturated or polar
functional groups. Antimalarial potency did not dimin-
ish for the two isomers (5, 6) of 1 but did drop off
significantly when the two methyl groups of 6 were
replaced with tert-butyl groups (7) (Table 2). For the six
tetramethyl tetraoxane isomers 8-13, potency was
maintained in 8, decreased slightly in 9, and was lost
entirely in 13; 10-12 were 2-4-fold more potent than
1 but were still less potent than artemisinin. Tetraox-
anes 14 and 15, analogues of 10 where two of the methyl
groups were replaced with isopropyl groups, were less
potent than 10, although 14 was as potent as tetraoxane
prototype 1. We suggest that, like the 1,1,10,10- and
1,5,10,14-tetramethyl-substituted tetraoxane analogues,9
the densely substituted 16 and 17, the bis-geminal
Table 1. Antimalarial Activity of 1,10-Dialkyl-Substituted
Analogues of Tetraoxane 1 (WR 148999) against P. falciparum
in Vitro
IC50 (nM)a
compd R D6 W2
1 methyl 55 32
2 ethyl 23 19
3 propyl 84 39
4 tert-butyl >300 160
artemisinin 8.4 7.3
arteether 2.7 1.4
a Average of n g 2.
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methyl-substituted 13, and the di-tert-butyl-substituted
4 and 7 were either inactive or weakly active due to
steric effects preventing or hindering peroxide bond
access to parasite heme.10 Finally we note that with one
exception (10), these tetraoxanes (Tables 1 and 2), like
artemisinin, were more potent against the chloroquine-
resistant W2 clone than against the chloroquine-sensi-
tive D6 clone of P. falciparum, although in each case
the potency difference was unremarkable.
To select tetraoxanes for subsequent po experiments,
the eight most potent tetraoxanes, along with arteether
as a control, were administered sc b.i.d. (64 mg/kg/day)
to P. berghei-infected mice on days 3, 4, and 5 post-
infection (Table 3). Tetraoxanes 6 and 12 were among
this group of eight tetraoxanes, even though 6 and 12
are known to be substantially less effective than 1 in
the sc single-dose Rane test. We note that there was no
correlation between in vitro IC50 data and either reduc-
tion of parasitemia or survival data. As measured by
suppression of parasitemia, tetraoxanes 10 and 11 were
equal to and tetraoxanes 8 and 14 were superior to 1.
On the other hand, survival data indicated that tet-
raoxanes 6, 8, and 10 were nearly as effective and
tetraoxanes 2 and 11 were better than 1. From this sc
in vivo data it is also clear that each of the tetraoxanes
was much less active than arteether. On the basis of
the combined in vitro and sc in vivo data, tetraoxanes
1, 10, 11, and 14, along with artemisinin and arteether
as controls, were administered po b.i.d. (128 mg/kg/day)
to P. berghei-infected mice on days 3, 4, and 5 post-
infection (Table 4). At this dose, tetraoxanes 10, 11, and
14 cured between 40% and 60% of the infected animals.
In comparison, artemisinin and tetraoxane 1 produced
no cures, whereas arteether cured 100% of the infected
animals.
Neurotoxicity. Even though reported clinical neu-
rotoxicity for the semisynthetic artemisinins is very
rare,13 neurotoxicity may be a potential drawback for
antimalarial peroxides. Indeed, in work initiated at the
Walter Reed Army Institute of Research, several of the
artemisinins have produced demonstrable neurotoxicity
in cell culture14 and in animal models.15 Thus, we
thought it useful to assess the relative neurotoxicity of
these tetraoxanes using a neurite outgrowth assay.16
Data in Table 5 show IC50’s against the NB2a neuro-
blastoma cell line14,16 with artemether and dihydroar-
temisinin as controls. In this screen, we note that
artemether is nonneurotoxic, whereas dihydroartemisi-
nin, the presumed metabolite of all of the semisynthetic
artemisinins,5 is quite neurotoxic. While we have previ-
ously observed that cell proliferation in NB2a cells is
not significantly more sensitive to dihydroartemisinin
than a comparable function in a nonneuronal cell line,
when NB2a cells are induced to differentiate, their
sensitivity to dihydroartemisinin increases.17 This con-
tributes to our confidence that the neurite outgrowth
assay more closely reflects potential selective neurotox-
icity. The IC50’s for the tetraoxanes ranged from 1 to
40 íM. Although tetraoxane prototype 1 (WR 148999)
had an IC50 of 8 íM in this experiment, previous data14
for 1 revealed that this compound was devoid of neu-
rotoxicity against either the NB2a or NG108-15 neuro-
blastoma cell lines. There was no apparent relationship
between tetraoxane structure and neurotoxicity, nor was
Table 2. Antimalarial Activity of Alkyl-Substituted
Tetraoxanesa against P. falciparum in Vitrob
IC50 (nM)c
compd R D6 W2
5 2,11-dimethyl 76 51
6 3,12-dimethyl 23 21
7 3,12-di-tert-butyl 200 100
8 1,2,10,11-tetramethyl 50 43
9 1,3,10,12-tetramethyl 110 49
10 1,4,10,13-tetramethyl 15 19
11 2,3,11,12-tetramethyl 12 10
12 2,4,11,13-tetramethyl 30 15
13 3,3,12,12-tetramethyl >1000 >1000
14 1,10-diisopropyl-4,13-dimethyl 47 37
15 4,13-diisopropyl-1,10-dimethyl 140 94
16 1,3,3,10,12,12-hexamethyl >1000 >1000
17 2,2,4,4,11,11,13,13-octamethyl >1000 >1000
a The 1,1,10,10- and 1,5,10,14-tetramethyl analogues were
inactive (ref 9). b For controls, see Table 1. c Average of n g 2.
Table 3. Antimalarial Activity of Tetraoxanes Administered sc




no. of mice dead/
day died
1 64 11 1/8 2/10 1/16 1/18
2 64 28 1/8 2/10 1/18 1/20
6 64 22 2/10 1/12 1/13 1/15
8 64 3 1/9 2/10 1/12 1/13
10 64 13 1/8 1/9 1/10 1/12 1/15
11 64 14 1/9 2/10 1/18 1/19
12 64 82 1/7 3/8 1/10
14 64 7 1/8 2/9 1/10 1/13
arteether 64 0 7/Cb
control 74 1/7 2/8 1/9 1/10
a Compounds were administered sc b.i.d. on days 3, 4, and 5
post-infection. b Survival beyond 60 days is considered curative (C).
Table 4. Antimalarial Activity of Tetraoxanes Administered
Orally to Mice Infected with P. berghei
compd mg/kg/daya no. of mice dead/day diedb
1 128 3/12 2/13 1/20 1/24
10 128 1/9 1/26 3/C
11 128 1/15 1/17 1/18 2/C
14 128 1/8 2/16 1/32 3/C
artemisinin 128 1/13 3/14 1/26
arteether 128 5/C
control 1/7 5/8 1/9
a Compounds were administered po b.i.d. on days 3, 4, and 5
post-infection. b Survival beyond 60 days is considered curative (C).







1 8.4 11 4.4
2 9.3 12 6.7
3 4.5 13 2.0
4 3.4 14 37
5 16 15 40
6 1.1 16 1.4
7 2.8 17 3.6
8 2.1 artemether 351
9 >1 dihydroartemisinin 0.22
10 17
a Average of n ) 3.
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there any correlation between antimalarial activity
(Tables 1 and 2) and neurotoxicity for these seventeen
tetraoxanes.
Discussion
In this work we identified five tetraoxanes with in
vitro potency superior to that of prototype tetraoxane
1, yet the most potent tetraoxane of the group (11) was
still 1.4-fold less potent than artemisinin and was
significantly less potent than arteether. Given the
apparent potency barrier of the alkyl-substituted tet-
raoxane class, a significant improvement in oral activity
now becomes a critical issue if these compounds can be
considered as potential replacements for the semisyn-
thetic artemisinins. In this respect, we were partially
successful, as three tetraoxanes to emerge from this
work had better oral activity than either artemisinin
or tetraoxane 1 but had weaker oral activity than
arteether. On the basis of data from 14 we suspect that
oral activity for these tetraoxanes is more a function of
drug metabolism than poor absorption, but we per-
formed no pharmacokinetic experiments to confirm this
hypothesis. Another potential criterion to consider for
this class of compounds is neurotoxicty,13-17 and from
our in vitro data, it is clear that some of the tetraoxanes
were only some 5-10-fold less neurotoxic than dihy-
droartemisinin. Nonetheless, more detailed studies us-
ing in vivo models and subsequent cyto- and histopatho-
logical experiments would be necessary to assess whether
neurotoxicity would disqualify these compounds from
further consideration.
A new synthetic method18 in which trimethylsilyl
derivatives of geminal bis-hydroperoxides are reacted
with ketones in the presence of trimethylsilyl trifluo-
romethanesulfonate now permits the synthesis of non-
symmetrical tetraoxanes. This advance should substan-
tially expand the possibilities for tetraoxane design19
since this new synthetic method is not symmetry-limited
as is the acid-catalyzed peroxidation of ketones. With
this new technology17 available, we hope that the results
presented here, combined with our previous data on
tetraoxanes substituted at the 1 and 10 positions with
unsaturated and polar functional groups, provide a good
basis on which to move forward in the search for more
orally active20 tetraoxane antimalarials.
Experimental Section
Melting points are uncorrected. 1H (300 MHz) and 13C (75
MHz) NMR spectra were recorded on a Varian XL-300
spectrometer using CDCl3 as a solvent. All chemical shifts are
reported in parts per million (ppm) and are relative to internal
(CH3)4Si for 1H and CDCl3 (77.0 ppm) for 13C NMR. Micro-
analyses were performed by M-H-W Laboratories, Phoenix, AZ.
Alkyl-Substituted Cyclohexanones. 2-Methyl-, 2-ethyl-,
3-methyl-, 2,3-dimethyl-, 3,4-dimethyl-, 2,5-dimethyl-, 3,5-
dimethyl-, and 3,3,5,5-tetramethylcyclohexanone and (-)-
menthone were available from TCI or Aldrich Chemical Co.
4,4-Dimethyl- and 2,4,4-trimethylcyclohexanone were obtained
by hydrogenation (Pd-C)21 of the commercially available
enones. 2-Propyl- and 5-isopropyl-2-methylcyclohexanone were
prepared by hydrogenation of 2-allylcyclohexanone and car-
vone, respectively. 2,4-Dimethylcyclohexanone was obtained
by methylation of the morpholinoenamine of 4-methylcyclo-
hexanone as described by Stork et al.22
Tetraoxane Synthesis. Tetraoxanes 2, 3, 5, 8-11, and
13-17 were prepared on a 10-mmol scale via the H2SO4/CH3-
CN method developed by McCullough et al.12 using 50% H2O2
as previously described.8 In each case, product tetraoxanes
were isolated as white crystalline solids, stable at room
temperature in the solid state for years. Tetraoxanes are
rather stable peroxide compounds,23 and dispiro-tetraoxanes
derived from alkyl-substituted cyclohexanones are not friction-
sensitive.24 Although we have encountered no difficulties in
working with these tetraoxanes, routine precautions such as
the use of shields, fume hoods, and avoidance of metal salts
should be observed whenever possible.
1,10-Diethyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexa-
decane (2): yield, 24%; mp 103-104 °C (CH3CN); 1H NMR
0.87 (t, J ) 7.5 Hz, 6H), 1.12-1.95 (m, 20H), 2.78-3.00 (m,
2H); 13C NMR 12.18, 20.15, 22.30, 24.50, 26.58, 29.74, 45.33,
109.64; VPO MW 282, calcd MW 284. Anal. (C16H28O4) C, H.
1,10-Dipropyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexa-
decane (3): yield, 7%; mp 82-84 °C (EtOH); 1H NMR 0.89
(t, J ) 6.9 Hz, 6H), 1.04-1.83 (m, 24H), 2.75-2.96 (m, 2H);
13C NMR 14.15, 20.71, 22.30, 24.41, 27.14, 29.32, 29.65, 43.21,
109.61; VPO MW 295, calcd MW 312. Anal. (C18H32O4) C, H.
2,11-Dimethyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexa-
decane (5): yield, 32%; mp 132-134 °C (CH3CN) (lit.25 mp
65-66 °C); 1H NMR 0.60-1.22 (m, 10H), 1.23-2.00 (m, 12H),
3.09 (br s, 2H); 13C NMR 21.50 (br s), 22.00, 28.61, 29.16 (br
s), 31.43 (br s), 34.14, 37.67 (br s), 39.61 (br s), 108.64; VPO
MW 272, calcd MW 256.
1,2,10,11-Tetramethyl-7,8,15,16-tetraoxadispiro[5.2.5.2]-
hexadecane (8): yield, 4%; mp 158-160 °C (CH3CN/H2O 4:1);
1H NMR 0.90 (d, J ) 6.4 Hz, 6H), 1.05 (d, J ) 6.8 Hz, 6H),
0.90-1.20 (m, 2H), 1.25-1.80 (m, 12H), 3.12-3.30 (m, 2H);
13C NMR 10.63, 20.09, 21.54, 30.46, 34.74, 34.96, 45,24, 109.30;
VPO MW 290, calcd MW 284. Anal. (C16H28O4) C, H.
1,3,10,12-Tetramethyl-7,8,15,16-tetraoxadispiro[5.2.5.2]-
hexadecane (9): yield, 20%; mp 145-147 °C (CH3CN); 1H
NMR 0.90 (t, J ) 6.2 Hz, 6H), 1.00 (t, J ) 6.9 Hz, 6H), 0.82-
1.93 (m, 14H), 3.08-3.31 (m, 2H); 13C NMR 13.75, 21.72, 30.26,
30.94, 32.16, 38.85, 39.56, 108.90; VPO MW 283, calcd MW
284. Anal. (C16H28O4) C, H.
1,4,10,13-Tetramethyl-7,8,15,16-tetraoxadispiro[5.2.5.2]-
hexadecane (10): yield, 26%; mp 144-146 °C (EtOH); 1H
NMR 0.80-1.20 (m, 16H), 1.30-1.85 (m, 10H), 3.05-3.26 (m,
2H); 13C NMR 13.53, 21.93, 28.97, 30.82, 34.30, 38.67, 38.73,
109.06; VPO MW 285, calcd MW 284. Anal. (C16H28O4) C, H.
2,3,11,12-Tetramethyl-7,8,15,16-tetraoxadispiro[5.2.5.2]-
hexadecane (11): the precipitate was treated with HClO4/
HAc to remove impurities; yield, 6% (mixture of 2 diasteromers
2.2:1); mp 103-104 °C (CH3CN/H2O 4:1); 1H NMR major
isomer, 0.85 (d, J ) 7.0 Hz, 12H), 1.21-2.08 (m, 14H), 2.45-
2.85 (m, 2H); minor isomer, 0.93 (d, J ) 6.3 Hz, 12H), 1.21-
2.08 (m, 14H), 2.98-3.20 (m, 2H); 13C NMR 12.24, 18.13 (br
s), 19.18, 19.66, 24.60 (br s), 27.23 (br s), 27.78 (br s), 28.26
(br s), 30.96, 32.40, 34.65 (br s), 38.43, 108.66; VPO MW 285,
calcd MW 284. Anal. (C16H28O4) C, H.
3,3,12,12-Tetramethyl-7,8,15,16-tetraoxadispiro[5.2.5.2]-
hexadecane (13): yield, 29%; mp 191-192 °C (CH3CN); 1H
NMR 0.72-0.97 (m, 6H), 0.95 (s, 6H), 1.16-1.46 (m, 8H) 1.47-
1.73 (m, 4H), 2.13-2.51 (m, 4H); 13C NMR 25.52 (br s), 27.74,
28.17 (br s), 29.91, 34.38 (br s), 34.98 (br s), 108.33; VPO MW
258, calcd MW 284. Anal. (C16H28O4) C, H.
1,10-Diisopropyl-4,13-dimethyl-7,8,15,16-tetraoxa-
dispiro[5.2.5.2]hexadecane (14): yield, 20%; mp 97-98 °C
(CH3OH); [R]27D -84.4° (c 0.1, CHCl3); 1H NMR 0.76-1.27 (m,
22H), 1.30-1.92 (m, 10H), 2.23-2.59 (m, 2H), 3.02-3.37 (m,
2H); 13C NMR 18.60, 21.41, 21.94, 23.02, 24.52, 28.98, 34.58,
39.84, 49.89, 110.94; VPO MW 329, calcd MW 340. Anal.
(C20H36O4) C, H.
4,13-Diisopropyl-1,10-dimethyl-7,8,15,16-tetraoxa-
dispiro[5.2.5.2]hexadecane (15): yield, 26%; mp 140-142
°C (EtOH); 1H NMR 0.91 (d, J ) 6.5 Hz, 12H), 1.02 (d, J ) 6.8
Hz, 6H), 0.95-1.19 (m, 4H), 1.30-1.82 (m, 12H), 3.15-3.35
(m, 2H); 13C NMR 13.45, 19.54, 19.93, 29.18, 30.83, 32.26,
33.56, 39.10, 40.04, 109.40; VPO MW 344, calcd MW 340. Anal.
(C20H36O4) C, H.
1,3,3,10,12,12-Hexamethyl-7,8,15,16-tetraoxadispiro-
[5.2.5.2]hexadecane (16): yield, 34%; mp 158-159 °C (EtOH);
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1H NMR 0.80-1.05 (m, 18H), 1.10-1.70 (m, 10H), 1.84-2.05
(m, 2H), 2.95-3.13 (m, 2H); 13C NMR 13.68, 24.50, 26.42,
30.40, 32.07, 34.85, 35.26, 44.10, 109.13; VPO MW 315, calcd
MW 312. Anal. (C18H32O4) C, H.
2,2,4,4,11,11,13,13-Octamethyl-7,8,15,16-tetraoxadispiro-
[5.2.5.2]hexadecane (17): yield, 68%; mp 185-186 °C (CH3-
OH) (lit. mp 184-186 °C); 1H NMR 1.05 (s, 24H), 1.30 (s, 4H),
1.42 (br s, 4H); 2.17 (br s, 4H), 13C NMR 31.55 (br s), 31.73,
31.97 (br s), 40.53, 43.47, 51.97, 110.11.
Antimalarial Screens. In vitro activity against P. falci-
parum was determined using a modification of the semiauto-
mated microdilution technique of Desjardins et al.26 and
Milhous et al.27 Two P. falciparum malaria parasite clones,28
designated as Sierra Leone (D6) and Indochina (W2), were
used in susceptibility testing. The former is resistant to
mefloquine and the latter to CQ, pyrimethamine, sulfadoxine,
and quinine. Test compounds were dissolved in dimethyl
sulfoxide and solutions serially diluted with culture media.
Erythrocytes with 0.25-0.5% parasitemia were added to each
well of a 96-well microdilution plate to give a final hematocrit
of 1.5%. Inhibition of uptake of tritiated hypoxanthine was
used as an index of antimalarial activity. Results were initially
recorded as IC50 (ng/mL) values and then converted to nM
values.
In vivo activity against P. berghei was obtained against a
drug-sensitive KBG 173 strain of P. berghei. A modification
of the Thompson test29 was used to measure the sc and po
antimalarial activity of selected tetraoxanes. Five-week-old
CD-1 mice were inoculated on day 0 with 5  106 trophozoites
of P. berghei obtained from an infected mouse at 60% para-
sitemia, diluted with uninfected mouse blood, and injected
intraperitonealy. On each of days 3, 4, and 5, groups of five or
seven mice were treated b.i.d. with 64 (sc) or 128 (po) mg/kg
dose of tetraoxanes. Blood films were taken 1 day after
completion of drug treatment (day 6) and weekly thereafter
until day 60. Parasitemia values were determined from
Giemsa-stained blood films. Drug activity was evaluated by
suppression of parasitemia, extension of survival time, and
curative activity. Untreated mice survive on average 6.2 days.
Mice living 60 days post-infection and blood film negative were
considered cured. A drug was considered to be toxic if the mice
died before the untreated control mice.
Neurotoxicity Screen. As described by Fishwick et al.,16
neuroblastoma cells were grown in 25-mL culture flasks with
15 mL of medium in a humidified 37 °C incubator with 5%
CO2. Culture medium used for the NB2a cell proliferation
consisited of high glucose DMEM with Glutamax-1, supple-
mented with 5% (v/v) horse serum, 5% (v/v) fetal calf serum
and 100 units/mL penicillin plus 100 íg/mL streptomycin, with
optional 25 íg/mL gentamicin. NB2a cells were plated onto
48-well microtiter culture plates at a cell density of 15 000
cells/mL. After 24 h the cells were induced to differentiate and
generate neurites in the presence of the drugs, by the following
method: the proliferation medium was removed and replaced
with serum-free medium plus 0.5 mM dibutyryl cyclic AMP
containing the drugs at concentrations of 10 and 0.1 íM. The
cells were incubated for a further 24 h, after which neurite
outgrowth was measured.
Cells were fixed with 4% formaldehyde in phosphate-
buffered saline (PBS) for 20 min at room temperature, stained
for 10 min with Coomassie blue cell stain 0.6% (w/v) (Coo-
massie brilliant blue G in 10% (v/v) acetic acid, 10% (v/v)
methanol and 80% (v/v) PBS), and then washed with PBS and
distilled water. The cells were then viewed by a light micro-
scope (Zeiss Axiovert 35M) linked by a video camera to a
Kontron Vidas 2.0 image analyzer. Subsequently, 10 different
fields of approximately 20 cells were chosen for each drug and
control.
A program was written using the available functions of the
image analyzer in order to permit the automatic measurement
of the total length of neurites (in pixels) for the cells in a given
field and to express the results as the average length of
neurites/cell.
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